Loading clinical trials...
Loading clinical trials...
A Phase 1a/1b Study of a Novel Anti-PD-L1 Checkpoint Antibody (LY3300054) Administered Alone or in Combination With Other Agents in Advanced Refractory Solid Tumors (Phase 1a/1b Anti-PD-L1 Combinations in Tumors-PACT)
Conditions
Interventions
LY3300054
Ramucirumab
+3 more
Locations
14
United States
Tennessee Oncology PLLC
Nashville, Tennessee, United States
University of Texas MD Anderson Cancer Center
Houston, Texas, United States
The START Center for Cancer Care
San Antonio, Texas, United States
Cliniques Universitaires Saint-Luc
Brussels, Belgium
Universitair Ziekenhuis Antwerpen
Edegem, Belgium
Princess Margaret Hospital
Toronto, Ontario, Canada
Start Date
June 29, 2016
Primary Completion Date
May 22, 2020
Completion Date
June 27, 2024
Last Updated
September 27, 2024
NCT07489378
NCT07181681
NCT06257264
NCT07403721
NCT03340506
NCT07380334
Lead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions